S1120 Vedolizumab Is Effective for the Treatment of Chronic Inflammatory Conditions of the Pouch in a Prospective Multicenter Study
Edward L. Barnes(University of North Carolina at Chapel Hill), Hans Herfarth(University of North Carolina at Chapel Hill), Maia Kayal(Icahn School of Medicine at Mount Sinai), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai), Jennifer I. Barr(University of North Carolina at Chapel Hill), Taha Qazi(Cleveland Clinic), Chelsea Anderson(University of North Carolina at Chapel Hill), Peter Higgins(Michigan Medicine), Millie D. Long(University of North Carolina Health Care), Poonam Beniwal‐Patel(Medical College of Wisconsin), Laura H. Raffals, Parakkal Deepak(Washington University in St. Louis), Shannon Chang(Mayo Clinic in Florida), Raymond K. Cross(University of Maryland, Baltimore)
Cited by 1
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018
|Gastroenterology|2018|1.7k
ACG Clinical Guideline: Ulcerative Colitis in Adults
|The American Journal of Gastroenterology|2019|1.6k